Work

The role of antibody-drug conjugates in the treatment of lung cancer

Year: 2026

Type: article

Abstract: Over the las0t decades, lung cancer treatment has improved immensely, mainly due to the incorporation of new targeted treatments and immunotherapy. A relatively new and potentially highly effective class of drugs, antibody-drug conjugates (ADCs), has been introduced to the clinical setting and is currently under intense investigation, alone and in combination with other molecules. This study aims to summarize the latest data on ADCs for lung cancer treatment and to analyze their potential, toxicity profile, and challenges.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2026.1757564

Authors: Tanya Zlatanova, Aynura Changalova, Urska Janzic

Institutions: Acibadem City Clinic, University of Ljubljana

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801